Latest Thrombocytopenia Stories
THOUSAND OAKS, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) was honored with two 2009 Scrip Awards, winning for Best Overall Pipeline and for Best New Drug for NplateÂ® (romiplostim), at a Nov. 18 ceremony in London.
Heparin, a commonly used anticoagulant, can cause skin lesions, reports a study in CMAJ (Canadian Medical Association Journal).
BERLIN, June 7 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today released the results of a new study comparing Nplate(R) (romiplostim) to the medical standard of care (SOC) in non-splenectomised adult patients with chronic immune thrombocytopenic purpura (ITP).
WASHINGTON, March 26 /PRNewswire-USNewswire/ -- Two Miami-area residents pleaded guilty today in connection with a $10 million Medicare fraud scheme involving HIV infusion clinics, Acting Assistant Attorney General Rita M. Glavin of the Criminal Division and U.S. Attorney R.
First and Only Approved Platelet Producer in Europe Represents New Treatment Approach for Serious Chronic Autoimmune Disorder ZUG, Switzerland, Feb.
SHENYANG, China, Jan.
SAN FRANCISCO, Dec. 8 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today released updated results from the ongoing, open-label extension study of the long-term safety and efficacy of Nplate(TM) (romiplostim) in adult patients with chronic immune thrombocytopenic purpura (ITP).
CHESHIRE, Conn., Dec. 8 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today reported positive results from AEGIS, an open-label registration study examining Soliris(R) (eculizumab) treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH).
SAN FRANCISCO, Dec.
- Emitting flashes of light; glittering.